---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-084112"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:35:45.027694+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEO Wa'el Hashad steps down; Than Powell interim CEO; Joshua Hare Executive Chairman

## Summary
- Wa'el Hashad resigned as CEO and board member effective August 27, 2025 to pursue other opportunities.
- Than Powell, former Chief Business Officer, appointed interim CEO effective September 4, 2025; base salary $500,000 with target bonus.
- Founder and CSO Dr. Joshua Hare appointed Executive Chairman; board plans national search for permanent CEO.
- Powell has 25+ years pharma/biotech leadership at GSK, Eli Lilly, Surescripts, and Epulate.

## SEC filing metadata
- accession: 0001213900-25-084112
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025084112/0001213900-25-084112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025084112/ea0255905-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-084112
- JSON: https://secwatch.observer/filing/0001213900-25-084112.json
- Plain text: https://secwatch.observer/filing/0001213900-25-084112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.